Mass. Mover

Aveo Oncology seeks FDA approval for kidney cancer drug

Aveo currently has more than 300 employees.


Aveo currently has more than 300 employees.


Aveo Oncology has submitted a new drug application to the Food and Drug Administration for a potential treatment for advanced kidney cancer. The Cambridge company has a deal with Japanese drug maker Astellas Pharma Inc. to commercialize tivozanib in some other countries. The application asks the FDA for approval to market tivozanib in the United States for patients with advanced renal cell carcinoma. An estimated 250,000 people are diagnosed with kidney cancer annually.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of